HI
BCLI

Harbour Investments’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History

Harbour Investments’s Portfolio BCLI Stock Details BCLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-3,559
Closed -$3.99K – 3756
2025
Q2 		$3.99K Buy
+3,559
New +$3.98K ﹤0.01% 2960
2023
Q4 		– Sell
-53
Closed -$159 – 3132
2023
Q3 		$159 Sell
53
-45
-46% -$1.02K ﹤0.01% 2900
2023
Q2 		$3.04K Hold
98
– – ﹤0.01% 2430
2023
Q1 		$4.87K Sell
98
-21
-18% -$609 ﹤0.01% 2283
2022
Q4 		$2.92K Sell
119
-57
-32% -$2.13K ﹤0.01% 2415
2022
Q3 		$7K Hold
176
– – ﹤0.01% 2046
2022
Q2 		$7K Buy
+176
New +$7.93K ﹤0.01% 2046
2021
Q4 		$18K Sell
293
-258
-47% -$12.7K ﹤0.01% 1701
2021
Q3 		$27K Sell
551
-79
-13% -$4.16K ﹤0.01% 2126
2021
Q2 		$36K Hold
630
– – ﹤0.01% 1986
2021
Q1 		$36K Buy
+630
New +$47.6K ﹤0.01% 1865

Other funds holding BCLI

Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
BSB
Bangor Savings Bank Bangor, Maine $1.36B AUM 19.29% 1-Year Est. Return
VWA
VSM Wealth Advisory Hunt Valley, Maryland $376M AUM 21.56% 1-Year Est. Return
SPIA
Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return
DJSG
D.J. St. Germain Springfield, Massachusetts $2.78B AUM 23.87% 1-Year Est. Return

Harbour Investments's BCLI Position: Q3 2025 in Review

Harbour Investments sold out of BRAINSTORM CELL THERAPUTC (BCLI) in Q3 2025, closing a stake of 3,559 shares — an estimated $3.99K sold.

Harbour Investments first reported a position in BCLI in Q1 2021 and held it in 11 quarters. The position peaked at $36K in Q2 2021. 5 funds tracked by Wall St. Rank hold BCLI as of Q3 2025.

  • Harbour Investments reported no remaining BRAINSTORM CELL THERAPUTC position as of Q3 2025 after selling out during the quarter.
  • Harbour Investments sold 3,559 BRAINSTORM CELL THERAPUTC shares in Q3 2025, an estimated $3.99K.
  • Harbour Investments first reported a position in BRAINSTORM CELL THERAPUTC in Q1 2021 and held it in 11 quarters.
  • Harbour Investments's BRAINSTORM CELL THERAPUTC position peaked at $36K in Q2 2021.
  • 5 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q3 2025.

Based on Harbour Investments's 13F filing for Q3 2025, filed 12 Nov 2025.